A new role at a cell-free tumor DNA oncology testing company Sysmex-Inostics 1
With digital PCR OncoBEAM and NGS Plasma SafeSEQ technologies sensitive to 0.02% and 0.05% MAF respectively, expect to hear more from Sysmex-Inostics for biomarker development, companion diagnostic commercialization and patient testing It isn’t unusual for me to be found at different conferences, whether ASHG, AGBT, AACR or occasionally Molecular Tri-Con […]
